Home News Company in the news

iX Biopharma obtains approval and registration of male erectile dysfunction drug in Singapore

Felicia Tan
Felicia Tan10/20/2020 08:45 AM GMT+08  • 1 min read
iX Biopharma obtains approval and registration of male erectile dysfunction drug in Singapore
The drug will be supplied via licensed medical practitioners in Singapore.
Font Resizer
Share to WhatsappShare to FacebookShare to LinkedInMore Share
Scroll to top
Follow us on Facebook and join our Telegram channel for the latest updates.

iX Biopharma has obtained approval and registration by the Health Sciences Authority (HSA) for Silcap, a sildenafil drug that is used in the treatment of male erectile dysfunction on Oct 20.

The drug, which is iX Biopharma’s second treatment for male erectile dysfunction after Wafesil, has been designed as a novel small capsule, which sets it apart from existing alternatives which are typically delivered in tablet form.

Silcap is the first capsule sildenafil product to obtain marketing approval in Singapore.

iX Biopharma also supplies Silcap and Wafesil in Australia since obtaining approval and registration in 2018.

See Also: Phillip Securities initiates 'buy' for iX Biopharma on prospect of turning profitable in FY21

“Apart from offering a unique value proposition when compared to existing sildenafil products in the market, Silcap® ’s approval continues to reaffirm our ability to bring products successfully from clinical development to registration and launch,” says Eva Tan, director of corporate and commercial strategy of iX Biopharma.

Silcap is available in dosage strengths of 25 mg and 50 mg in pack sizes of 4, 8 and 12 capsules and will be supplied via licensed medical practitioners.

Shares in iX Biopharma closed flat at 26.5 cents on Oct 19.

Loading next article...
The Edge Singapore
Download The Edge Singapore App
Google playApple store play
Keep updated
Follow our social media
Subscribe to The Edge Singapore
Get credible investing ideas from our in-depth stock analysis, interviews with key executives, corporate movements coverage and their impact on the market.
© 2022 The Edge Publishing Pte Ltd. All rights reserved.